Quanterix Highlights Compelling Benefits of Akoya Biosciences Acquisition
Quanterix (NASDAQ: QTRX) has reaffirmed the strategic benefits of its proposed acquisition of Akoya Biosciences, aimed at creating the first integrated solution for ultra-sensitive biomarker detection in blood and tissue. The merger will expand Quanterix's addressable market to $5 billion across neurology, immunology, and oncology, with an additional $10 billion opportunity in Alzheimer's Disease diagnostics.
The company projects $40 million in annual run-rate cost synergies by the end of 2026, with $20 million expected within the first year post-closing. Quanterix anticipates reaching $1 billion in revenue with 15% EBIT margins within five years after closing, with positive free cash flow expected by 2026.
The company also addressed nominations from Kent Lake PR for three board candidates, stating that Kent Lake's analysis contains flawed assumptions and inaccurate information. The transaction is expected to close in Q2 2025, pending shareholder approvals and closing conditions.
Quanterix (NASDAQ: QTRX) ha riaffermato i benefici strategici della sua proposta di acquisizione di Akoya Biosciences, mirata a creare la prima soluzione integrata per la rilevazione ultra-sensibile dei biomarcatori nel sangue e nei tessuti. La fusione espanderà il mercato indirizzabile di Quanterix a 5 miliardi di dollari nei settori della neurologia, immunologia e oncologia, con un'ulteriore opportunità di 10 miliardi di dollari nella diagnostica della malattia di Alzheimer.
L'azienda prevede 40 milioni di dollari in sinergie di costo annuali entro la fine del 2026, con 20 milioni attesi nel primo anno dopo la chiusura. Quanterix anticipa di raggiungere 1 miliardo di dollari di fatturato con margini EBIT del 15% entro cinque anni dalla chiusura, con un flusso di cassa libero positivo previsto entro il 2026.
L'azienda ha anche affrontato le nomination da parte di Kent Lake PR per tre candidati al consiglio, affermando che l'analisi di Kent Lake contiene assunzioni errate e informazioni inaccurate. La transazione dovrebbe chiudersi nel secondo trimestre del 2025, in attesa delle approvazioni degli azionisti e delle condizioni di chiusura.
Quanterix (NASDAQ: QTRX) ha reafirmado los beneficios estratégicos de su propuesta de adquisición de Akoya Biosciences, destinada a crear la primera solución integrada para la detección ultra-sensible de biomarcadores en sangre y tejidos. La fusión ampliará el mercado direccionable de Quanterix a 5 mil millones de dólares en neurología, inmunología y oncología, con una oportunidad adicional de 10 mil millones de dólares en diagnósticos de la enfermedad de Alzheimer.
La empresa proyecta 40 millones de dólares en sinergias de costos anuales para finales de 2026, con 20 millones esperados en el primer año posterior al cierre. Quanterix anticipa alcanzar 1 mil millones de dólares en ingresos con márgenes EBIT del 15% dentro de cinco años después del cierre, con flujo de caja libre positivo esperado para 2026.
La compañía también abordó las nominaciones de Kent Lake PR para tres candidatos a la junta, afirmando que el análisis de Kent Lake contiene suposiciones defectuosas e información inexacta. Se espera que la transacción se cierre en el segundo trimestre de 2025, a la espera de aprobaciones de los accionistas y condiciones de cierre.
Quanterix (NASDAQ: QTRX)는 Akoya Biosciences 인수 제안의 전략적 이점을 재확인하며, 혈액 및 조직에서 초민감 바이오마커 탐지를 위한 최초의 통합 솔루션을 만드는 것을 목표로 하고 있습니다. 이번 합병을 통해 Quanterix의 목표 시장은 신경학, 면역학 및 종양학 분야에서 50억 달러로 확대되며, 알츠하이머병 진단에서 추가로 100억 달러의 기회를 갖게 됩니다.
회사는 2026년 말까지 연간 4천만 달러의 비용 시너지를 예상하고 있으며, 첫 해에는 2천만 달러가 기대됩니다. Quanterix는 인수 후 5년 이내에 10억 달러의 매출과 15%의 EBIT 마진에 도달할 것으로 예상하며, 2026년까지 긍정적인 자유 현금 흐름이 기대됩니다.
회사는 또한 Kent Lake PR의 이사회 후보 3명에 대한 지명을 언급하며, Kent Lake의 분석이 잘못된 가정과 부정확한 정보를 포함하고 있다고 밝혔습니다. 이번 거래는 주주 승인 및 마감 조건이 충족되면 2025년 2분기에 마감될 것으로 예상됩니다.
Quanterix (NASDAQ: QTRX) a réaffirmé les avantages stratégiques de sa proposition d'acquisition de Akoya Biosciences, visant à créer la première solution intégrée pour la détection ultra-sensible des biomarqueurs dans le sang et les tissus. La fusion élargira le marché adressable de Quanterix à 5 milliards de dollars dans les domaines de la neurologie, de l'immunologie et de l'oncologie, avec une opportunité supplémentaire de 10 milliards de dollars dans le diagnostic de la maladie d'Alzheimer.
La société prévoit 40 millions de dollars d'économies de coûts annuelles d'ici la fin de 2026, avec 20 millions attendus au cours de la première année suivant la clôture. Quanterix anticipe d'atteindre 1 milliard de dollars de revenus avec des marges EBIT de 15% dans les cinq ans suivant la clôture, avec un flux de trésorerie libre positif attendu d'ici 2026.
La société a également abordé les nominations de Kent Lake PR pour trois candidats au conseil, affirmant que l'analyse de Kent Lake contient des hypothèses erronées et des informations inexactes. La transaction devrait être conclue au deuxième trimestre 2025, sous réserve des approbations des actionnaires et des conditions de clôture.
Quanterix (NASDAQ: QTRX) hat die strategischen Vorteile seiner vorgeschlagenen Übernahme von Akoya Biosciences bekräftigt, die darauf abzielt, die erste integrierte Lösung zur ultra-sensiblen Biomarkererkennung in Blut und Gewebe zu schaffen. Die Fusion wird den adressierbaren Markt von Quanterix auf 5 Milliarden Dollar in den Bereichen Neurologie, Immunologie und Onkologie erweitern, mit zusätzlichen 10 Milliarden Dollar an Möglichkeiten in der Alzheimer-Diagnostik.
Das Unternehmen prognostiziert 40 Millionen Dollar an jährlichen Kostensynergien bis Ende 2026, wobei 20 Millionen im ersten Jahr nach dem Abschluss erwartet werden. Quanterix rechnet damit, innerhalb von fünf Jahren nach dem Abschluss 1 Milliarde Dollar Umsatz mit 15% EBIT-Margen zu erreichen, wobei bis 2026 ein positiver Cashflow erwartet wird.
Das Unternehmen hat auch die Nominierungen von Kent Lake PR für drei Vorstandskandidaten angesprochen und erklärt, dass die Analyse von Kent Lake fehlerhafte Annahmen und ungenaue Informationen enthält. Die Transaktion wird voraussichtlich im 2. Quartal 2025 abgeschlossen, vorbehaltlich der Genehmigungen der Aktionäre und der Abschlussbedingungen.
- Expands addressable market to $15B total
- $40M annual cost synergies by 2026
- Projects $1B revenue within 5 years
- 15% EBIT margins expected within 5 years
- Positive free cash flow projected by 2026
- Faces opposition from Kent Lake shareholders
- Transaction completion subject to shareholder approval risk
Insights
Quanterix's planned acquisition of Akoya represents a significant strategic pivot with ambitious growth targets that deserve investor attention. The combined entity aims to bridge blood-based and tissue-based biomarker detection—creating technology synergies that could accelerate development in the liquid biopsy space.
The financial projections reveal substantial confidence in this integration, with management targeting
These projections warrant scrutiny. While the combined addressable market opportunity of
The shareholder opposition from Kent Lake adds a layer of governance complexity that could impact deal approval. Interestingly, the proxy battle emerges despite the absence of disclosed acquisition terms or valuation metrics in this announcement—a notable omission for investors attempting to evaluate the transaction's merits.
The Kent Lake director nominations represent a significant escalation in shareholder activism against Quanterix's proposed Akoya acquisition. By submitting three board candidates ahead of the 2025 Annual Meeting, Kent Lake is effectively launching a proxy contest to influence or potentially derail the transaction.
Quanterix's defensive language—characterizing Kent Lake's analysis as containing "significantly flawed financial assumptions" and "factually inaccurate information"—suggests material disagreements about valuation and strategic rationale. The timing is particularly notable, occurring after the February 13 S-4 filing but before shareholder votes.
This development introduces substantial execution risk for the transaction. While the company maintains its Q2 2025 expected closing timeline, the pending proxy battle could delay approvals or affect voting outcomes. The board's composition critique from Kent Lake directly challenges the directors' expertise in capital allocation and M&A evaluation.
The situation creates a governance inflection point for Quanterix. Management must now not only secure regulatory approvals but also win the shareholder narrative battle around transaction merits. For investors, this activist challenge provides a rare window into dissenting views on a transformative transaction, though lacking specific details of Kent Lake's financial criticisms hampers complete evaluation of competing perspectives.
Comments on Director Nominations Received from Kent Lake
Quanterix’s proposed acquisition of Akoya is the result of a rigorous and thorough Board evaluation consistent with its commitment to position the Company for long-term growth. With enhanced scale and a strengthened financial foundation, Quanterix will accelerate the execution of its strategic plan and deliver significant value to shareholders:
-
Expanded Addressable Market. The addition of Akoya’s cutting-edge spatial biology capabilities will unlock a high-growth
$5 billion $10 billion
-
Synergy Generation: With extensive diligence and deep familiarity with Akoya’s platform, Quanterix has clear line of sight to capture approximately
$40 million $20 million
-
Enhanced Scale and Profitability: With expected positive free cash flow in 2026 and continued strong double-digit organic revenue growth, Quanterix expects the transaction will allow it to multiply its revenue to approximately
$1 billion 15% within five years following close.
Kent Lake Nominations
Quanterix confirmed that Kent Lake PR LLC (“Kent Lake”) has submitted notice nominating three candidates to stand for election to the Quanterix Board of Directors at the Company’s 2025 Annual Meeting of Shareholders.
The Company welcomes engagement with its shareholders and has attempted to engage constructively with Kent Lake and will continue to do so. Kent Lake’s recent statements, however, contain significantly flawed financial assumptions, factually inaccurate information and fail to recognize the compelling and strategically necessary rationale of the transaction. Kent Lake’s director nominations are a clear attempt to obfuscate the long-term value creation opportunity the acquisition of Akoya presents.
The Quanterix Board has been built thoughtfully to ensure that it is composed of directors with outstanding track records and the right mix of skillsets to successfully oversee the Company’s strategic plan, which includes deep expertise across the life sciences industry with a particular focus on diagnostics, as well as commercial strategy, strategic planning, corporate governance and capital markets experience.
The Quanterix Board will evaluate Kent Lake’s nomination notice and present its recommendation with respect to the election of directors in the Company’s proxy statement, which will be filed with the Securities and Exchange Commission (“SEC”) and mailed to all shareholders eligible to vote at the 2025 Annual Meeting. The date of the 2025 Annual Meeting has not yet been announced. Quanterix shareholders are not required to take any action with respect to the election of directors at this time.
Quanterix and Akoya are progressing toward closing. On February 13, 2025, Quanterix filed a registration statement on Form S-4, which contains a preliminary joint proxy statement of Quanterix and Akoya and a preliminary prospectus of Quanterix, with the SEC. The transaction is expected to close in the second quarter of 2025, subject to applicable approvals by both companies’ shareholders and satisfaction of other customary closing conditions.
Goldman Sachs & Co. LLC is serving as financial advisor to Quanterix and Covington & Burling LLP is serving as its legal counsel in Quanterix’s acquisition of Akoya.
About Quanterix
From discovery to diagnostics, Quanterix’s ultrasensitive biomarker detection is fueling breakthroughs only made possible through its unparalleled sensitivity and flexibility. Quanterix’s Simoa® technology has delivered the gold standard for earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the Level of Quantification (LoQ). Its industry-leading precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Quanterix has been a trusted partner of the scientific community for nearly two decades, powering research published in more than 3,100 peer-reviewed journals.
IMPORTANT ADDITIONAL INFORMATION
In connection with the proposed acquisition of Akoya Biosciences, Inc. (“Akoya”) by Quanterix (the “Merger”), Quanterix filed with the
PARTICIPANTS IN THE SOLICITATION
Quanterix and Akoya and certain of their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of Quanterix or Akoya in respect of the proposed transaction. Information about Quanterix’s directors and executive officers is available in the Joint Proxy Statement/Prospectus, and other documents filed by Quanterix with the SEC. Information about Akoya’s directors and executive officers is available in the Joint Proxy Statement/Prospectus and Akoya’s proxy statement dated April 23, 2024, for its 2024 Annual Meeting of Stockholders, and other documents filed by Akoya with the SEC. Other information regarding the persons who may, under the rules of the SEC, be deemed participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, is contained in the Joint Proxy Statement/Prospectus and other relevant materials to be filed with the SEC regarding the proposed transaction when they become available. Investors should read the definitive Joint Proxy Statement/Prospectus carefully when it becomes available before making any voting or investment decisions. You may obtain free copies of these documents from Quanterix or Akoya as indicated above.
NO OFFER OR SOLICITATION
This communication shall not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval with respect to the Merger, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
Statements included in this press release which are not historical in nature or do not relate to current facts are intended to be, and are hereby identified as, forward-looking statements for purposes of the safe harbor provided by Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are based on, among other things, projections as to the anticipated benefits of the Merger as well as statements regarding the impact of the Merger on Quanterix’s and Akoya’s business and future financial and operating results, the amount and timing of synergies from the Merger and the closing date for the Merger. Words and phrases such as “may,” “approximately,” “continue,” “should,” “expects,” “projects,” “anticipates,” “is likely,” “look ahead,” “look forward,” “believes,” “will,” “intends,” “estimates,” “strategy,” “plan,” “could,” “potential,” “possible” and variations of such words and similar expressions are intended to identify such forward-looking statements. Quanterix and Akoya caution readers that forward-looking statements are subject to certain risks and uncertainties that are difficult to predict with regard to, among other things, timing, extent, likelihood and degree of occurrence, which could cause actual results to differ materially from anticipated results. Such risks and uncertainties include, among others, the following possibilities: the occurrence of any event, change or other circumstances that could give rise to the right of one or both of the parties to terminate the Merger Agreement; the outcome of any legal proceedings that may be instituted against Quanterix or Akoya; the failure to obtain necessary regulatory approvals (and the risk that such approvals may result in the imposition of conditions that could adversely affect the combined company or the expected benefits of the Merger) and stockholder approvals or to satisfy any of the other conditions to the Merger on a timely basis or at all; the possibility that the anticipated benefits and synergies of the Merger are not realized when expected or at all, including as a result of the impact of, or problems arising from, the integration of the two companies or as a result of the strength of the economy and competitive factors in the areas where Quanterix and Akoya do business; the possibility that the Merger may be more expensive to complete than anticipated; diversion of management’s attention from ongoing business operations and opportunities; potential adverse reactions or changes to business or employee relationships, including those resulting from the announcement or completion of the Merger; changes in Quanterix’s share price before the closing of the Merger; risks relating to the potential dilutive effect of shares of Quanterix common stock to be issued in the Merger; and other factors that may affect future results of Quanterix, Akoya and the combined company. Additional factors that could cause results to differ materially from those described above can be found in the Joint Proxy Statement Prospectus, and in other documents Quanterix and Akoya file with the SEC, which are available on the SEC’s website at www.sec.gov.
All forward-looking statements, expressed or implied, included in this press release are expressly qualified in their entirety by the cautionary statements contained or referred to herein. If one or more events related to these or other risks or uncertainties materialize, or if Quanterix’s or Akoya’s underlying assumptions prove to be incorrect, actual results may differ materially from what Quanterix and Akoya anticipate. Quanterix and Akoya caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made and are based on information available at that time. Neither Quanterix nor Akoya assumes any obligation to update or otherwise revise any forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements were made or to reflect the occurrence of unanticipated events except as required by federal securities laws.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250303071118/en/
Media
Marissa Klaassen
media@quanterix.com
Or
Jim Golden / Tali Epstein
Collected Strategies
QTRX-CS@collectedstrategies.com
Investor Relations
Joshua Young
ir@quanterix.com
Or
Geoffrey Weinberg / Michael Verrechia / Bill Dooley
Sodali & Co
QTRX@info.sodali.com
Source: Quanterix Corporation
FAQ
What are the projected cost synergies from Quanterix's acquisition of Akoya Biosciences?
What is the total addressable market for QTRX after the Akoya acquisition?
When is the Quanterix-Akoya merger expected to close?
What are Quanterix's financial projections following the Akoya acquisition?
